R3HDM1 and cancer: From the result, fasudil, imatinib, NU1025, and 4,5-Dianilinophthalimide exhibited significantly lower scores across most cancer types, suggesting their potential to inhibit R3HDM1-mediated oncogenic effects (Figure 6F).